SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing high volatility as traders debate whether recent drops signal a larger market correction or just a temporary pullback, fueled by concerns around AI valuations and potential recession indicators. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, closely watching key support levels and VIX movements. The conversation includes speculation about the Fed's next moves and the impact of economic data on market direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is trending down, sparking debate about an AI bubble. The community is actively discussing whether the drop is a market correction, profit-taking, or manipulation by institutional investors. Some also point to comments from a Fed official raising concerns about valuations as a contributing factor.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a strong Q3 earnings report that included raised FY26 guidance and a surge in e-commerce sales, with discussion around its potential move to the Nasdaq. Community talking points include whether Walmart is a safe haven during market volatility and the impact of potential government shutdowns on SNAP benefits and consumer spending at Walmart stores.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant downturn, sparking debates about its role as a store of value and potential for further decline. Community discussions revolve around possible bottom levels, with some anticipating a substantial bounce while others fear a continued slide. The broader market context, including potential impacts from macroeconomic factors and liquidations, is also fueling uncertainty and volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MELI is experiencing a significant downturn, with discussions focusing on a recent shelf filing and potential competition from Amazon as possible catalysts. The community is expressing concerns about the stock's performance, with some seeing the dip as a buying opportunity while others are wary of further declines. Broader macroeconomic factors and regional risks in Latin America are also being considered as contributing factors to the volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to discussions around warrant redemptions and their impact on stock dilution, with a deadline approaching soon. The community is debating the company's long-term potential, its management, and comparing it to other rare earth companies, with some expressing concerns about recent performance and others highlighting its strategic partnerships and focus on heavy rare earth elements. News around the company's deal with Solvay and Saudi Arabian Mining Company (Maaden), meant to develop a rare earth refinery, has brought some recent attention.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as it hits fresh 52-week lows, with the community debating whether it's a buying opportunity or if further downside is expected due to its correlation with Bitcoin. Despite the recent price drop, some traders are noting unusual call option activity, suggesting contrarian bullish bets, while others point to potential liquidation levels and debt concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alberta Investment Management Corp Buys Shares of 133,200 Zura Bio Limited $ZURA

Alberta Investment Management Corp bought a new position in Zura Bio Limited (NASDAQ:ZURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...

Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)

Chardan Capital reissued a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday...

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst...

Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell

Wall Street Zen lowered shares of Zura Bio from a "hold" rating to a "sell" rating in a research report on Sunday...

Zura Bio (NASDAQ:ZURA) Issues Earnings Results

Zura Bio (NASDAQ:ZURA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02...

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today...

Zura Bio (NASDAQ:ZURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Zura Bio from a "sell" rating to a "hold" rating in a research report on Saturday...

Novartis (NVS) on Monday announced positive results from its late-stage trials evaluating its investigational drug Ianalumab in adults with active Sjögren's disease.Ianalumab is a novel fully human monoclonal antibody being investigated for its potential to treat various B-cell-driven autoimmune diseases. The drug’s mechanism of action targets B cells in two ways: combining B cell depletion and interruption of BAFF-R-mediated signals of B cell function and survival.Guggenheim said the positive updates give evidence that BAFF-signaling disruption and B cell depletion are "a valid approach" for hard-to-treat autoimmune diseases, which has a positive read-through for Zura Bio (ZURA). Shares of <a href="https://stocktwits.com/symbol/ZURA">Zura</a>, which Guggenheim deems "significantly undervalued," traded 3% higher at the time of writing.Novartis <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-announces-both-ianalumab-phase-iii-clinical-trials-met-primary-endpoint-patients-sjogrens-disease">said</a> that its two late-stage trials for Sjögren's disease met the primary endpoint of demonstrating statistically significant improvements in disease activity. Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_12_02_03_PM_png_fdf22daf95.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:02 p.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure>Sjögren’s disease is a systemic, chronic autoimmune disorder that causes inflammation and tissue damage, impacting the entire body. It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.“These Phase III studies mark a significant milestone. We look forward to engaging with health authorities to discuss these findings in the near future,” said Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis.Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease, the company said, while adding that it plans to submit the drug to health authorities globally.NYSE-listed shares of the company traded 1% higher at the time of writing.Ianalumab originated from Novartis’ early collaboration with MorphoSys AG, a company which it later acquired in 2024. In clinical trials, Ianalumab showed promising efficacy and a favorable safety profile in Sjögren’s disease, systemic lupus erythematosus, and immune thrombocytopenia.While NVS shares are up by 21% this year, ZURA is down 42%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/avantor-responds-to-activist-investor-engine-capital-letter/chru67IRde5">Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Drug Shows Improvement In Sjögren's Disease In Late-Stage Trials: Analyst Deems Data Positive For Zura Bio As Well

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.

Equity

Novartis now sees the potential for the drug to become the first and only targeted treatment approved for patients with the disease.


Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that...

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the...

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

ZURA
Zura Bio Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZURA News

ZURAZura Bio Ltd - Ordinary Shares - Class A